{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:56:23Z","timestamp":1794020183809,"version":"4.8.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>For the clinical evaluation of the efficacy of cellular immunotherapy it is necessary to analyze the effector functions of T cells against primary leukemic target cell populations which are usually considerably heterogeneous caused by differential maturation stages of the leukemic cells. An appropriate assay should not only allow the quantitative analysis of rapid cell death induction as measured by the conventional 51Cr release assay but also of the more slowly executing pathways of T-cell-induced apoptosis occurring within days instead of hours which cannot be measured using this method. Furthermore, it should dissect the differential susceptibility to T-cell-induced cell death of various target cell subpopulations and characterize the malignant precursor cells capable of producing malignant progeny. To fulfill these requirements we developed a new assay based on carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling of the target cell population combined with antibody staining of specific cell populations and addition of fluorescent microbeads to quantitatively monitor target cell death occurring within a longer time frame up to at least 5 days. This new assay facilitates the analysis of differential recognition of distinct cell types within a heterogeneous target cell population and allows simultaneously evaluation of the proliferative status of surviving target cells in response to relevant cytokines. (Blood. 2004;103: 2677-2682)<\/jats:p>","DOI":"10.1182\/blood-2003-06-2070","type":"journal-article","created":{"date-parts":[[2003,11,24]],"date-time":"2003-11-24T20:14:27Z","timestamp":1069704867000},"page":"2677-2682","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":151,"title":["New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population"],"prefix":"10.1182","volume":"103","author":[{"given":"Inge","family":"Jedema","sequence":"first","affiliation":[{"name":"From the Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"van der Werff","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene\u0301e M. Y.","family":"Barge","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Willemze","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217292853500_REF1","doi-asserted-by":"crossref","unstructured":"Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 1998;29: 301-313.","DOI":"10.3109\/10428199809068567"},{"key":"2020021217292853500_REF2","doi-asserted-by":"crossref","unstructured":"Smit WM, Rijnbeek M, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 1998;95: 10152-10157.","DOI":"10.1073\/pnas.95.17.10152"},{"key":"2020021217292853500_REF3","doi-asserted-by":"crossref","unstructured":"Falkenburg JHF, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94: 1201-1208.","DOI":"10.1182\/blood.V94.4.1201"},{"key":"2020021217292853500_REF4","doi-asserted-by":"crossref","unstructured":"Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol. 1998;10: 581-587.","DOI":"10.1016\/S0952-7915(98)80227-6"},{"key":"2020021217292853500_REF5","doi-asserted-by":"crossref","unstructured":"Waring P, Mullbacher A. Cell death induced by the Fas\/Fas ligand pathway and its role in pathology. Immunol Cell Biol. 1999;77: 312-317.","DOI":"10.1046\/j.1440-1711.1999.00837.x"},{"key":"2020021217292853500_REF6","doi-asserted-by":"crossref","unstructured":"Jedema I, Barge RM, Willemze R, Falkenburg JH. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G(1) phase of the cell cycle and can be increased by interferon treatment. Leukemia. 2003;17: 576-584.","DOI":"10.1038\/sj.leu.2402844"},{"key":"2020021217292853500_REF7","doi-asserted-by":"crossref","unstructured":"Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA- 2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100: 2742-2747.","DOI":"10.1073\/pnas.0530192100"},{"key":"2020021217292853500_REF8","unstructured":"Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 1968;14: 181-196."},{"key":"2020021217292853500_REF9","doi-asserted-by":"crossref","unstructured":"Bouma GJ, van der Meer-Prins PM, van Bree FP, Van Rood JJ, Claas FH. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum Immunol. 1992;35: 85-92.","DOI":"10.1016\/0198-8859(92)90015-F"},{"key":"2020021217292853500_REF10","doi-asserted-by":"crossref","unstructured":"Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115: 61-69.","DOI":"10.1016\/0022-1759(88)90310-9"},{"key":"2020021217292853500_REF11","doi-asserted-by":"crossref","unstructured":"Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243: 147-154.","DOI":"10.1016\/S0022-1759(00)00231-3"},{"key":"2020021217292853500_REF12","doi-asserted-by":"crossref","unstructured":"Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171: 131-137.","DOI":"10.1016\/0022-1759(94)90236-4"},{"key":"2020021217292853500_REF13","doi-asserted-by":"crossref","unstructured":"Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods. 2001;253: 177-187.","DOI":"10.1016\/S0022-1759(01)00359-3"},{"key":"2020021217292853500_REF14","doi-asserted-by":"crossref","unstructured":"Marin L, Minguela A, Torio A, et al. Flow cytometric quantification of apoptosis and proliferation in mixed lymphocyte culture. Cytometry. 2003;51A: 107-118.","DOI":"10.1002\/cyto.a.10007"},{"key":"2020021217292853500_REF15","doi-asserted-by":"crossref","unstructured":"Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods. 2001;249: 99-110.","DOI":"10.1016\/S0022-1759(00)00329-X"},{"key":"2020021217292853500_REF16","doi-asserted-by":"crossref","unstructured":"Lange B, Valtieri M, Santoli D, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 1987;70: 192-199.","DOI":"10.1182\/blood.V70.1.192.192"},{"key":"2020021217292853500_REF17","doi-asserted-by":"crossref","unstructured":"Voogt PJ, Fibbe WE, Marijt WA, et al. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 1990;335: 131-134.","DOI":"10.1016\/0140-6736(90)90003-N"},{"key":"2020021217292853500_REF18","doi-asserted-by":"crossref","unstructured":"Jedema I, Barge RMY, Nijmeijer BA, Willemze R, Falkenburg JHF. Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia. 2003;17: 2049-2051.","DOI":"10.1038\/sj.leu.2403085"},{"key":"2020021217292853500_REF19","doi-asserted-by":"crossref","unstructured":"van der Hoorn MAWG, van Luxemburg-Heijs SAP, van Bergen CAM, Bongaerts R, Willemze R, Falkenburg JHF. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia. Methods. 2003;31: 113-119.","DOI":"10.1016\/S1046-2023(03)00120-8"},{"key":"2020021217292853500_REF20","unstructured":"Voogt PJ, Fibbe WE, Veenhof WF, et al. Cell-mediated lysis of human hematopoietic progenitor cells. Leukemia. 1987;1: 427-431."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/7\/2677\/1696835\/zh800704002677.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/7\/2677\/1696835\/zh800704002677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T18:23:29Z","timestamp":1581531809000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/7\/2677\/18238\/New-CFSEbased-assay-to-determine-susceptibility-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-06-2070","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}